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CD4+ TcellsserveasmasterregulatorsoftheadaptiveimmuneresponsetoHBV.However,CD4+ T-cellsubsetsareheterogeneous,
andit remains unknown how the antiviralagents aﬀectthediﬀerent CD4+ Tcell subtypes.To this end,the expressions ofsignature
transcription factors and cytokines of CD4+ T-cell subtypes were examined in hepatitis B patients before and after treatment with
telbivudine. Results showed that, upon the rapid HBV copy decrease induced by telbivudine treatment, the frequencies and related
cytokines of Th17 and Treg cells were dramatically decreased, while those for Th2 cells were dramatically increased. No obvious
changes were observed in Th1 cell frequencies; although, IFN-γ expression was upregulated in response to telbivudine treatment,
suggesting another cell source of IFN-γ in CHB patients. Statistical analyses indicated that Th17 and Tr1 (a Treg subtype) cells
were the most sensitive subpopulations of the peripheral blood CD4+ T cells to telbivudine treatment over 52weeks. Thus, Th17
and Tr1 cells may represent a suitable and eﬀective predictor of responsiveness during telbivudine therapy. These ﬁndings not only
improve our understanding of hepatitis pathogenesis but also can aid in future development of appropriate therapeutic strategies
to control viral hepatitis.
1.Introduction
Persistent infection with the hepatitis B virus (HBV) remains
a challenging global health problem. Currently more than
370 million people are chronically infected, and this rate is
estimated to increase by 4 million per year. Hepatitis B is
a leading cause of chronic hepatitis, cirrhosis and hepato-
cellular carcinoma and accounts for about 1 million deaths
annually [1].
The pathogenesis of liver damage during an HBV infec-
tion is immune-mediated and is dependent on the balance
between viral replication and the host HBV-speciﬁc T-cell
response [2, 3]. In patients with an acute self-limiting HBV
infection, a multispeciﬁc T-cell response is important for
control of the infection [4, 5]. Patients with a chronic HBV
infection, however, lack such a vigorous multispeciﬁc T-cell
response and instead exhibit a weak or undetectable virus-
speciﬁc T-cell response [4]. This condition of T cell hypore-
sponsiveness is frequently associated with high viral and/or
antigen load in chronic hepatitis B (CHB) patients [6, 7].
Therefore, early inhibition and decrease of HBV replication
is likely essential for the recovery of T-cell reactivity in CHB
patients.
S e v e r a lc u r r e n t l ya v a i l a b l ed r u g sa r ea p p r o v e df o rt r e a t -
ment of HBV infection and in routine use, including inter-
feron-α (IFN-α), pegylated IFNα-2a, lamivudine, adefovir,
and entecavir. The newly developed nucleoside analogue,
telbivudine, has also been approved for clinical use by both2 Mediators of Inﬂammation
the US Food and Drug Administration and the European
Medicines Evaluation Agency [8]. It has potent and speciﬁc
anti-HBV activity, which is triggered upon phosphoryla-
tion by cellular kinases. The active triphosphate form of
telbivudine can then inhibit the HBV DNA polymerase
activity by competing with its natural substrate thymidine
5 -triphosphate [9]. In this manner, telbivudine can not only
eﬀectively suppress HBV replication and propagation but
also decrease the consequent liver injury [10–12]. Moreover,
these drug eﬀects are also accompanied by marked increases
in CD4+ and CD8+ T cell responsiveness [13–17]. Chen et
al. demonstrated that telbivudine treatment can lead to an
increasedfrequencyofperipheralbloodCD4+Tlymphocytes
and an augmented proliferative response of HBV-speciﬁc T
cells to the hepatitis B core antigen (HBcAg) [18].
CD8+ T cells are considered the key cellular eﬀectors
mediating HBV clearance from the liver, and they produce
this eﬀect through a Fas-dependent and perforin-inde-
pendent process [19]. However, induction of the CD8+ T
cell response is dependent upon the presence of CD4+ T
cells, as evidenced by an HBV model in which CD4+ Tc e l l s
were found to serve as the master regulators of the adaptive
immune response [19]. Boni et al. also demonstrated that
CD8+ T cell responses were enhanced markedly in HBV
infection and showed that this enhancement followed the
reconstitution of CD4+ reactivity and the decline of viral
load induced by lamivudine therapy [13, 15]. Collectively,
these data indicated a pivotal role for CD4+ T cells in anti-
HBV immunity. However, CD4+ T cells are a heterogeneous
population, comprised of at least four subtypes (Th1,
Th2, Treg, and Th17 cells), each with distinctive functions.
Dissecting the precise roles of each CD4+ Tc e l ls u b t y p ew i l l
provide insights into the host mechanisms underlying the
pathogenesis and persistence of HBV infection.
To gain a more detailed understanding of the roles
played by each of the circulating CD4+ T-cell subpopulations
in chronic HBV infection, we performed a longitudinal
investigation of the changes in CD4+ T-cell subpopulations
following rapid decrease of viral load induced by telbivudine
treatment. Furthermore, we determined which of the main
subtypes were closely correlated with the eﬃcacy of such
treatment. The ﬁndings from our study are expected to
open new avenues for treatment of chronic hepatitis B based
on induction of the beneﬁcial CD4+ Tc e l ls u b t y p e sb y
combining antiviral agents and speciﬁc T-cell stimulators or
suppressors.
2.Methods and Materials
2.1. Patients. Thirty-eight chronic hepatitis B patients (24
males and 14 females, aged 21 to 50 years; Table 1), negative
for markers of human immunodeﬁciency virus, hepatitis C,
and hepatitis D infection, were enrolled from the Hepatitis
Clinic of Southwest Hospital (Chongqing, China). Hep-
arinized blood samples were collected from each patient at
baseline (0) and at 12, 24, 36, and 52 weeks after telbivudine
treatment (600mg orally per day). Control blood samples
were donated by 23 healthy individuals (15 males and 8
Table 1:ClinicalcharacteristicsoftheCHBpatientsatstudyenroll-
ment.
Patient characteristics at baseline, n = 38
Sex, male (%) 24 (63)
Age, yearsa 28 (21–50)
HBV DNA, copies/mLa 4.6 × 108 (1.4 × 107–4.2 × 109)
ALTb, units/La 134.5 (53–549)
HBsAga 13683 (2056–138933)
HBeAg-positive, n (%) 38 (100)
ALT: alanine aminotransferase; HBsAg: hepatitis B surface antigen.
aMedian (range); bnormal value: ≤40IU/L.
females, aged 25 to 45 years). All patients were positive for
HBV e antigen (HBeAg) at baseline and had biopsy-proven
chronic hepatitis with various degrees of liver inﬂammation
and ﬁbrosis. Written informed consent was obtained from
each patient prior to study participation, and the study
protocolwasapprovedbytheEthicsCommitteeofSouthwest
Hospital.
2.2. Cell Isolation. Peripheral blood mononuclear cells
(PBMCs) were isolated from fresh heparinized peripheral
blood by using the Optiprep Nycoprep Lymphoprep kit
(Axis-shield, Oslo, Norway) according to the manufacturer’s
protocol. Isolated cells were suspended in Trizol reagent
(Invitrogen, Karlsruhe, Germany) and frozen in −80◦C
until use for mRNA extraction. The plasma from the
same peripheral blood sample was collected and frozen in
−80◦C until use in the enzyme-linked immunosorbent assay
(ELISA).
2.3. Cytokines. Cytokines in serum (after removal of ﬁbrino-
gen from plasma) were detected by conventional sandwich
ELISA using detection and capture Abs from eBioscience
(IL-17A and IL-23; San Diego, CA, USA) and Dakewei (IL-
4, IL-10, TGF-β1, and IFN-γ; Beijing, China). Extinction
spectra and cytokines were measured at 450nm on an ABS-
MONO spectrophotometer (s/n 1105; Beckman, Krefeld,
Germany) and with the accompanying Multimode Analysis
software. ELISAs were carried out following the respective
manufacturer instructions. Standards and samples were run
in duplicate.
2.4. Reverse Transcriptase Polymerase Chain Reaction (RT-
PCR) and Quantitative (q)PCR. Extraction of total RNA
was performed using the Trizol reagent (Invitrogen) and
following the manufacturer instructions. The isolated RNA
(2.5μg) was applied as template to a reverse transcription
reaction using the One Step SYBR PrimeScript RT-PCR kit
(Perfect Real Time; TaKaRa, Shiga, Japan). The qPCR reac-
tion was performed with an Mx3000P qPCR system (Agilent
Technologies, Waldbronn, Germany) using the SYBR Premix
Ex Taq (Perfect Real Time; TaKaRa) and following the man-
ufacturer guidelines. The following gene-speciﬁc primer
pairs were used: FOXP3: (forward) 5 -AAG GAA AGG AGG
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Figure 1: Clinical characteristics of CHB patients after treatment with telbivudine. Serum samples were collected from 38 CHB patients
treated with telbivudine at ﬁve time points after treatment initiation. HBV DNA level was detected by qPCR. Serum HBsAg concentration
was detected by ELISA. Serum ALT was measured by the CHEMIX-180 automated biochemistry analyzer (Japanese SYSMEX Corporation).
∗∗∗P<0.001 versus baseline (0).
AAA CC-3 ; T-bet: (forward) 5 -ATG TGA CCC AGA TGA
TTG TG-3  and (reverse) 5 -CGG AAA GTA AAG ATA TGC
GTG-3 ;R O R γt, (forward) 5 -ACT CAA AGC AGG AGC
AAT GGA A-3  and (reverse) 5 -AGT GGG AGA AGT CAA
AGA TGG A-3 ; GATA3, (forward) 5 -TAG CTG TAA GGC
ATG AAG GAT G-3  and (reverse) 5 -CTG GTG AAC GGT
AAC ACT GAT T-3 ; GAPDH, (forward) 5 -CGG AGT CAA
CGG ATT TGG TCG TAT-3  and (reverse) 5 -AGC CTT
CTC CAT GGT GGT GAA GAC-3 . For each primer pair, a
standardcurve wasgeneratedusing diﬀerent cDNA dilutions
to calculate mRNA expression of the respective gene. Next,
each mRNA expression level was normalized to the GAPDH
expression in the respective cDNA preparation. Controls
were arbitrarily set to 1.0, and gene induction was calculated
as fold increase compared to the controls.
2.5. Statistical Analysis. Statistical analysis was performed
with the SPSS software program v14.0 (Chicago, IL, USA).
All results at diﬀerent time points are presented as means ±
standard error of the mean (SEM) or as median with
range. Diﬀerences among groups were compared using the
Student’st-testandMann-WhitneyU test.Correlationswere
evaluated using Spearman’s rank correlation test for non-
parametric values. Diﬀerences were considered statistically
signiﬁcant at P<0.05.
3. Results
3.1. Serological and Virological Response to Telbivudine Ther-
apy in CHB Patients. During the entire 52-week therapy
course, the viremia of all 38 patients showed an immediate
sharp decline to a low or undetectable level, which was
maintained until the end of the therapy (Figure 1). In
addition, eight patients were found to have seroconverted
to the hepatitis B e antibody (anti-HBe) after 36 weeks
of treatment; the remaining 30 patients stayed HBeAg-
positivethroughoutthe52weeksoftreatment.Inaccordance
with the sharp decrease observed in HBV copy number in
serum,theHBsAgconcentrationwasfoundtoberemarkably
reduced after 12 weeks of treatment, and this low level
remained stable through the remainder of the treatment
course (Figure 1). Following the rapid virus clearance after
treatment, liver injury was greatly alleviated, as evidenced by
remarkably reduced serum ALT levels starting at 12 weeks of
treatment (Figure 1).
3.2. Telbivudine Decreases the Population of Treg and Th17
Cells but Increases the Amount of Th2 Cells. Since the above
results demonstrated excellent therapeutic eﬀects of tel-
bivudine on HBV propagation inhibition and liver injury
alleviation, we investigated the mechanisms underlying such
therapeutic eﬀects. CD4+ T cells are known to play very
important roles in antivirus immunity and to mediate
liver injury. Thus, we investigated whether CD4+ T-cell
subpopulations were inﬂuenced by telbivudine treatment by
using qPCR to measure the expression levels of CD4+ T-cell
subtype-speciﬁc transcription factors. Results showed that
telbivudine had diﬀerent eﬀects on the diﬀerent CD4+ T-
cell subtypes (Figure 2). The mean expression level of T-
bet, the critical transcription factor of Th1 cells, in PBMCs
became obviously increased after 12 weeks of treatment
but then declined and stabilized at the baseline level until
the end of the treatment course (week 52). Furthermore,
the T-bet expression levels in HBV-infected patients were
markedly lower than those in healthy controls throughout
the entire treatment course. Unlike the Th1-speciﬁc T-bet
expression proﬁle, the critical transcription factor of Th2
cells, GATA3, increased gradually in response to treatment,
eventually reaching the level of the healthy controls after 52
weeks of treatment. For the Th17 cells, the expression of
RORγt in PBMC was found to decrease steadily in response
to telbivudine treatment, reaching the normal level at 52
weeks of treatment. Similarly, the mRNA expression of the
Treg-speciﬁc FOXP3 gene was found to decrease over time
in response to telbivudine treatment, until the level reached
close to the normal level (P = 0.03).
3.3. Telbivudine Inﬂuences the Expression of the Key Cytokines
in CD4+ T-Cell Subtypes Asynchronously. Each of the CD4+
T-cell subtypes diﬀerentiates from na¨ ıve CD4+ T-cells in
certain permissive microenvironments and secretes the dis-
tinctive proﬁles of cytokines. Based on this knowledge, we



































































































Figure 2: Changes in mRNA expressions of critical transcriptional factors for CD4+ T-cell subpopulations in response to telbivudine
treatment. PBMCs from the healthy controls and CHB patients treated with telbivudine were used to detect the relative mRNA expression
levels of the CD4+ T-cell subtype-speciﬁc transcription factors by qPCR. ∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001 versus the respective
baseline or 52-week value. Ns: no signiﬁcance.
intheserumofpatientsbyusingELISA.AsshowninTable 2,
telbivudine inﬂuenced the expression of all the key cytokines
in CD4+ T-cell subtypes, except for IFN-γ, in a pattern very
similar to that observed for the signature transcriptional
factors (Figure 2). Telbivudine treatment caused a gradual
decrease in IL-17 and IL-23 (Th17-related cytokines) and
TGF-β and IL-10 (Treg cell-related cytokines) but increased
IL-4 (Th2 cell cytokine). No signiﬁcant change was observed
in the T-bet expression levels after 52 weeks of treatment
(Figure 2); however, there was a signiﬁcant increase in the
expression of Th1-related cytokine, IFN-γ,a f t e r2 4w e e k so f
treatment (Table 2). All the detected cytokines restored to
normal levels except IL-10 that was signiﬁcantly decreased
but still higher than healthy control at the end of treatment
(Table 2).
3.4. Correlation between the CD4+ T-Cell Subtypes and HBV
DNA Levels in Telbivudine-Treated CHB Patients. Telbivu-
dineamelioratedthevirologicalandserologicalresponseand
altered the expressions of various CD4+ T-cell transcription
factors and the related signature cytokines in CHB patients.
Wenextexaminedwhethertheimprovedclinicalphenotypes
were caused by the altered CD4+ T-cell population in
telbivudine-treated CHB patients by analyzing the correla-
tion between the two.
Telbivudine is highly selective for HBV DNA and inhibits
viral DNA synthesis with no eﬀect on human DNA or
other viruses. Our results clearly indicated that telbivudine
suppressed the HBV propagation; however, following the
decreaseofHBVcopiesinserum,thefrequencyandfunction
of the CD4+ T-cell subpopulations were also changed.
Since the particular CD4+ T-cell subtype inﬂuenced by the
decrease of HBV copies can reﬂect the mechanisms involved
in HBV infection, we further analyzed the relationship
between CD4+ T-cell subtypes and HBV DNA level. A
signiﬁcant correlation was found between the Th17-related
transcription factor and HBV DNA levels in the telbivudine-
treated CHB patients. No correlation was observed between
the levels of Th1, Th2, and Treg cell-related transcription
factors and the HBV DNA copy number (Figure 3).
Accordingly, when the relationship between signature
cytokine levels of the CD4+ T-cell subtypes and HBV copyMediators of Inﬂammation 5
Table 2: Telbivudine treatment inﬂuence on CD4+ T-cell subtype-speciﬁc cytokines expressions in PBMCs from HBV patients.
Time points
(weeks) IFN-γ (pg/mL) IL-4 (pg/mL) IL-17 (pg/mL) IL-23 (pg/mL) TGF-β (pg/mL) IL-10 (pg/mL)
Baseline 7.459 ±1.206 3.612 ±0.370 16.480 ± 1.983 10.030 ±1.454 23.170 ±2.891 23.970 ±2.571
12 11.720 ±2.566 8.090 ±1.469∗∗ 12.800 ± 1.485 6.990 ±0.864 23.440 ±2.593 14.030 ±1.885∗∗
24 19.380 ±3.170∗∗ 9.100 ±1.892∗∗ 8.440±1.216∗∗∗ 6.100 ±1.009∗ 18.610 ±2.365 7.820 ±0.908∗∗∗
36 17.790 ±2.580∗∗ 7.540 ±1.575∗ 7.980±0.995∗∗∗ 5.760 ±0.618∗∗ 14.950 ±2.668∗ 6.746 ±0.903∗∗∗
52 23.350±2.139∗∗∗ 10.900±1.488∗∗∗ 7.140±0.796∗∗∗ 4.740 ±0.722∗∗ 10.610±1.759∗∗∗ 8.890 ±0.973∗∗∗
Healthy 26.240±3.066∗∗∗ 14.710±2.080∗∗∗ 5.980±0.605∗∗∗ 3.370±0.517∗∗∗ 8.830 ±0.931∗∗∗ 3.530±0.332∗∗∗,#
Data are shown as mean ± SEM. ∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001 versus the respective baseline; #P<0.001 versus 52-week value.
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Figure 3: Correlation between the signature transcription factors of CD4+ T-cell subtypes and HBV DNA level. Expressions of the signature
transcription factors for each of the CD4+ T-cell subtypes and HBV DNA level at various time points of treatment (baseline and weeks 12,
24, 36, and 52) are indicated on the plots by diamonds. Error bars indicate SEM.
number was analyzed, almost no correlation was found for
IFN-γ or IL-4; however, strong correlations were found for
both IL-23 and IL-17 with HBV copy number (Figure 4).
For the Treg signature cytokine analysis, no correlation was
found between TGF-β and HBV copy number, but we did
determine that another Treg-related cytokine, IL-10, was
correlated signiﬁcantly with HBV copy number (Figure 4).
4. Discussion
Chronic infections eventually led to an exhaustion of the
CD8+ T-cell population. Evidence has indicated that a
robust, early CD4+ T-cell response is critical for inducing
and sustaining eﬀective CD8+ T-cell activity [20, 21]. In
HBV infection, CD4+ T cells serve as master regulators6 Mediators of Inﬂammation
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Figure 4: Correlation between the signature cytokines of CD4+ T-cell subtypes and HBV DNA level. Expression of the signature cytokines
for each of the CD4+ T-cell subtypes and HBV DNA level at various time points of treatment (baseline and weeks 12, 24, 36, and 52) are
indicated on the plots by diamonds. Error bars indicate SEM.
of the adaptive immune response to HBV [19]. Treatment
with the potent nucleoside analogue, lamivudine, leads
to reconstitution of CD4+ T cell activity and subsequent
induction of the CD8+ T cell response, as well as decline in
the viral load [13, 15]. These observations indicate the key
roles played by CD4+ T cells in HBV infection.
CD4+ T cells are a heterogeneous population, consisting
offunctionally-distinctTh1,Th2,Treg,andTh17cells.Thus,
we designed the current study to investigate the subpop-
ulation frequencies and related cytokines of each CD4+ T
subset before and after telbivudine therapy to gain insights
intothedetailedmechanismsofHBVpathogenesis.ThetotalMediators of Inﬂammation 7
expression level of cell type-speciﬁc transcription factors can
reﬂect the cell frequency directly; thus we measured the T-
bet, GATA-3, FOXP3, and RORγtm R N Al e v e l st or e p r e s e n t
the frequencies of the four CD4+ T-cell subsets, respectively.
Telbivudine is an L-nucleoside that is structurally related
to lamivudine and has recently been approved for use in
patients with chronic HBV infection. The multinational
GLOBE phase III study has shown that telbivudine treat-
ment was superior to lamivudine in its abilities to reduce
HBV load to undetectable levels, normalize serum ALT,
and improve the rates of HBeAg seroconversion in CHB
individuals; moreover, telbivudine was associated with less
viral resistance than lamivudine [11, 22, 23]. In the present
study, we also observed that telbivudine led to an early rapid
viral load reduction in all patients and continued to improve
the biochemical and virological parameters throughout the
52 weeks of treatment in patients with CHB, which further
provided supporting data for the excellent anti-HBV eﬀects
of telbivudine.
It has been reported that Th1 and Th2 immunity are
functionally impaired in chronic HBV patients [24], which
was also observed at baseline in our current study. We
further found that telbivudine-induced suppression of viral
replication had little eﬀect on Th1 cells of CHB patients.
The Th1 critical transcription factor, T-bet, had a much
lower expression level in CHB patients before treatment
than in healthy controls, but treatment did not restore the
expression to normal levels at any time. However, 52 weeks
of treatment led to signiﬁcant elevation of the Th1 signature
cytokine, IFN-γ. These results suggested that the observed
elevated IFN-γ was not principally derived from Th1 cells
in these patients, but instead may have originated from
other immune cells, such as natural killer T (NKT) cells.
It is possible that the antiviral treatment with telbivudine
signiﬁcantly increased the invariant (i) NKT cells, which
can produce IFN-γ and which are known to have decreased
programmed death-1 receptors in virally infected patients
[25]. It is also possible that the Th1 cell percentage was
actually elevated by telbivudine treatment in our patients,
but it is also possible that these cells moved from the
periphery to the liver tissue [26], masking detectable changes
by our study that relied on PBMC samples. Therefore, it is
reasonablethatweobservedasigniﬁcantcorrelationbetween
HBV DNA copy number and IFN-γ expressions, but not
a marked correlation between HBV DNA copies and T-bet
expression during telbivudine treatment.
In contrast to Th1, we found that Th2 cells were cor-
related with telbivudine-induced suppression of viral repli-
cation. The Th2 critical transcription factor, GATA-3, and
the Th2 signature cytokine, IL-4, expressions gradually and
steadily elevated to reach the normal level after 52 weeks
of therapy. Although the increase of GATA-3 expression
was not strongly correlated with the decrease of HBV DNA
copy number (P = 0.055), the IL-4 expression was strongly
correlated with HBV DNA copy number (P = 0.042). Such
relationship was also observed in a previous study of CHB
patients during long-term treatment with adefovir dipivoxil
[24].
Tregcellsplayanimportantroleintheimpairedimmune
response of chronic HBV infection. Patients with a chronic
HBV infection have increased percentages of CD4+CD25+
regulatory T cells in their peripheral blood [7, 27]. It has
been suggested that Treg can be induced through a repetitive
stimulation of T cells by the presence of high concentrations
of antigen for longer periods of time [27]. Our data from the
current study also showed that the Treg signature transcrip-
tion factor, FOXP3, expression was higher in CHB patients
than in healthy controls. Moreover, telbivudine treatment
could rapidly reduce the FOXP3 expression and maintain
it extremely low (to almost normal levels) throughout the
52 weeks of treatment, which was similar to the previously
reported eﬀect of adefovir on the Treg frequency in CHB
patients [28]. We further observed that the expressions of
Treg signature cytokines, TGF-β and IL-10, were remarkably
reduced by telbivudine treatment.
In accordance with our observation, a more recent study
also shows a decline in circulating CD4+CD25high Tregs
together with the decline in viral load and serum ALT
normalization after telbivudine treatment [29]. However,
that study has not further analyzed the correlation between
Tregs frequency and viral load. Here, in this study, statistical
analysis did not show any apparent correlation between
FOXP3 or TGF-β expressions and HBV DNA copy number;
instead, there existed signiﬁcant correlation between the IL-
10 level and HBV copy number.
Treg cells are a heterogeneous population and can
be subdivided into two specialized types of CD4+ Tregs
secreting either IL-10 (Tr1) or TGF-β (Th3) [30, 31]. In this
study, the Tr1 subpopulation was correlated with the HBV
copy number, but the Th3 subpopulation was not. It is very
possible that the total Treg frequency, which was indicated
in this study by total FOXP3 expression, does not correlate
with HBV copy number. These results suggest that future
analysis should be carried out with each Treg subtype to
gain a better understanding of the eﬀects of Treg cells on
HBV infection. In addition, the signiﬁcant decrease of IL-
10 that was observed in our study in response to telbivudine
treatment was not observed in a previous study of CHB
patients treated with adefovir [28], which might reﬂect the
diﬀerent mechanisms of the two drugs.
Inappropriate, excessive, and nonspeciﬁc Th17 eﬀector
responses may be involved in the pathogenesis of HBV-
associated liver inﬂammation and hepatocellular damage.
Th17 response, especially, may exacerbate the inﬂammatory
processes that lead to liver failure [32]. Our previous study
and the observation from Zhang’s group showed that IL-
17 and IL-23 are highly expressed in CHB patients and
are closely related to the serum viral load [33, 34]. In
the current study, telbivudine-induced reduction of HBV
DNA levels resulted in dramatic decreases of the Th17
critical transcription factor, RORγt, expression, which was
accompanied by a marked decrease in the Th17-related
cytokines, IL-17 and IL-23. Statistical analyses indicated that
the decrease of Th17 cell frequency and its related cytokines
was closely correlated to the reduction of HBV DNA levels,
indicating that Th17 cells were the most sensitive subtypes
to telbivudine-induced suppression of viral replication and8 Mediators of Inﬂammation
suggesting Th17 cells might represent the most important T
cell subtype involved in the pathogenesis of HBV infection.
5. Conclusions
The data in this study indicated that telbivudine is able to
diﬀerentially inﬂuence the CD4+ T-cell subsets in patients
withchronichepatitisBinfection.Suchtreatmentwasshown
to cause a dramatic decrease in the Th17 and Treg cell
frequencies and expressions of their related cytokines. In
contrast, treatment caused a dramatic increase in the Th2
cellsubtype.Whilenoobviouschangeswereobservedforthe
Th1 cell frequencies, the subtype-related IFN-γ expression
was upregulated by telbivudine treatment suggesting an
alternative cell source of IFN-γ in CHB patients treated
with the drug. Statistical analyses indicated that the Th17
and Tr1 cells were the most sensitive subpopulations of
the peripheral blood CD4+ T cells over the 52 weeks of
telbivudine treatment, and might represent suitable and
eﬀective markers of responsiveness during telbivudine ther-
apy. Collectively, these ﬁndings improve our understanding
of hepatitis pathogenesis and may be useful to develop novel
therapeutic strategies for controlling viral hepatitis.
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